As a mechanism of action of IVIg treatment for MG, it is reported that IVIg treatment expanded CTLA4+ Tregs by modulating antigen presenting DC, since CTLA4+ Tregs were underrepresented and functionally defective in MG patients (37). The gene discussed is CTLA4; the disease is myasthenia gravis.